News | February 24, 2026
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Subscribe To Our Newsletter & Stay Updated
